Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-24P (RNA, U6 small nuclear 24, pseudogene) is a genomic sequence derived from the U6 family of small nuclear RNAs (snRNAs), which are components of the spliceosome machinery responsible for splicing pre-messenger RNA in eukaryotic cells. However, as a pseudogene, RNU6-24P is a non-functional, processed duplication that does not produce a functional snRNA. Pseudogenes like RNU6-24P are often formed by retrotransposition and do not participate in normal cellular processes or splicing. As such, RNU6-24P lacks biological activity, clinical significance, or potential as a therapeutic target, and is primarily of interest in evolutionary genomics and studies of genome architecture. Although functional U6 snRNAs are commonly used as reference genes in molecular biology (e.g., RNU6-2), pseudogenes such as RNU6-24P have no such use and do not generate RNA products involved in gene regulation or disease. The presence of numerous U6 pseudogenes in the genome is thought to reflect retrotransposon activity rather than serving a biological function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 24, pseudogene (RNU6-24P).